Eurofins-Cerep SA (FR:ALECR) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Eurofins Cerep SA reported a decrease in 2023 revenue by 7.47% to 44,069 million euros, down from 47,628 million euros in 2022, with an operating profit of 6.46 million euros, also noting a decline from the previous year’s 11.48 million euros. Despite the market slowdown, the company is expanding through new platforms and strategic initiatives like ‘DiscoveryOne’ and partnerships with the University of Poitiers. Eurofins Cerep remains a leader in in-vitro pharmacology and is enhancing its integrated drug discovery services, offering comprehensive solutions to the pharmaceutical industry.
For further insights into FR:ALECR stock, check out TipRanks’ Stock Analysis page.